Related Experiment Video
Updated: Jun 19, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with
Emilia Sbardella1, Valentina Tomassini, Claudio Gasperini
1Departments of Neurological Sciences, Sapienza University, Rome, Italy. emilia.sbardella@uniroma1.it
Background:
Neutralizing antibodies (NAbs) against Interferon beta (IFNbeta) are reported to be associated with poor clinical response to therapy in multiple sclerosis (MS) patients. We aimed to quantify the contribution of NAbs to the sub-optimal response of IFNbeta treatment.
Methods:
We studied the prevalence of NAbs in MS patients grouped according to their clinical response to IFNbeta during the treatment period. Patients were classified as: group A, developing >or= 1 relapse after the first 6 months of therapy; group B, exhibiting confirmed disability progression after the first 6 months of therapy, with or without superimposed relapses; group C, presenting a stable disease course during therapy. A cytopathic effect assay tested the presence of NAbs in a cohort of ambulatory MS patients treated with one of the available IFNbeta formulations for at least one year. NAbs positivity was defined as NAbs titre >or= 20 TRU.
Results:
Seventeen patients (12.1%) were NAbs positive. NAbs positivity correlated with poorer clinical response (p < 0.04). As expected, the prevalence of NAbs was significantly lower in Group C (2.1%) than in Group A (17.0%) and Group B (17.0%). However, in the groups of patients with a poor clinical response (A, B), NAbs positivity was found only in a small proportion of patients.
Conclusion:
The majority of patients with poor clinical response are NAbs negative suggesting that NAbs explains only partially the sub-optimal response to IFNbeta.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Cross-reactivity
Multiple Sclerosis l: Introduction
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
